Ceptaris Earns FDA Approval for Valchlor to Treat Mycosis Fungoides-type CTCL

Ceptaris Therapeutics announced today that the U.S. Food and Drug Administration has granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. 

Mycosis fungoides is the most common type of CTCL. 

The first of its kind

Valchlor, therefore, becomes the first and only FDA-approved topical formulation of mechlorethamine (commonly known as nitrogen mustard). Valchlor is a gel applied topically once a day.

Said Youn H. Kim, M.D., Joanne and Peter Haas Jr. Professor for Cutaneous Lymphoma Research, professor of dermatology, and director of Multidisciplinary Cutaneous Lymphoma Clinic at Stanford University School of Medicine:

This is good news for patients and the treatment community. We now have the confidence of a FDA-approved product backed by evidence from a well-controlled clinical trial that demonstrated clinically meaningful responses in the majority of patients with stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma who have received prior skin-directed therapy.

About mechlorethamine

Mechlorethamine is a chemotherapy drug previously approved for intravenous treatment of mycosis fungoides. Prior to this approval, no FDA-approved topical mechlorethamine products were on the market. Only non-standardized, pharmacy-compounded petroleum ointment or aqueous-based topical preparations were available.

Source: Ceptaris

lymphoma roundup

More Articles

More Articles

In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. T cell lymphomas account for about...

Lymphomatoid Papulosis (LyP) is a rare skin disorder that involves cancerous looking skin lesions. It is more than a skin condition; it is the...

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma. It tends to develop in...

In general, a diagnosis of T-cell lymphoma denotes a poorer prognosis than a diagnosis of B-cell lymphoma. One of...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...